A multi-centre study to evaluate the effects of valsartan and the combination of valsartan and simvastatin on blood pressure (ambulatory and Std cuff) and on biochemical markers of endothelial function (hsCRP, MCP-1, serum F2 isprostanes, PAI-1, tPA, PICP, PIIINP, MMP9, MMP1, TIMP 1), safety and tolerability

Trial Profile

A multi-centre study to evaluate the effects of valsartan and the combination of valsartan and simvastatin on blood pressure (ambulatory and Std cuff) and on biochemical markers of endothelial function (hsCRP, MCP-1, serum F2 isprostanes, PAI-1, tPA, PICP, PIIINP, MMP9, MMP1, TIMP 1), safety and tolerability

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Dec 2006

At a glance

  • Drugs Simvastatin; Valsartan
  • Indications Dyslipidaemias; Essential hypertension; Hypercholesterolaemia; Hyperlipidaemia; Hypertension
  • Focus Pharmacodynamics; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 17 Dec 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top